MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-modulated Radiotherapy.
Adult
Aged
Biomarkers, Tumor
/ radiation effects
Female
Gene Expression Regulation, Neoplastic
/ radiation effects
Humans
Kaplan-Meier Estimate
Male
MicroRNAs
/ genetics
Middle Aged
Neoplasm Recurrence, Local
/ genetics
Radiotherapy, Intensity-Modulated
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ genetics
Treatment Outcome
Head and neck cancer
IMRT
locoregional control
miR-15b-5p
microRNA
radiotherapy
Journal
Cancer genomics & proteomics
ISSN: 1790-6245
Titre abrégé: Cancer Genomics Proteomics
Pays: Greece
ID NLM: 101188791
Informations de publication
Date de publication:
Historique:
received:
04
12
2018
revised:
17
12
2018
accepted:
18
12
2018
entrez:
10
3
2019
pubmed:
10
3
2019
medline:
14
6
2019
Statut:
ppublish
Résumé
Head and neck cancers are a heterogenous group of epithelial tumors represented mainly by squamous cell carcinomas (HNSCC), which are the sixth most common type of cancer worldwide. Surgery together with radiotherapy (RT) is among the basic treatment modalities for most HNSCC patients. Various biomarkers aiming to predict patients' response to RT are currently investigated. The reason behind this effort is, on one hand, to distinguish radioresistant patients that show weak benefit from RT and, on the other hand, reduce the ionizing radiation dose in less aggressive radiosensitive HNSCC with possibly less acute or late toxicity. A total of 94 HNSCC patients treated by definitive intensity-modulated radiotherapy were included in our retrospective study. We used a global expression analysis of microRNAs (miRNAs) in 43 tumor samples and validated a series of selected miRNAs in an independent set of 51 tumors. We identified miR-15b-5p to be differentially expressed between patients with short and long time of locoregional control (LRC). Kaplan-Meier analysis confirmed that HNSCC patients with higher expression of miR-15b-5p reach a significantly longer locoregional relapse-free survival compared to patients expressing low levels. Finally, multivariable Cox regression analysis revealed that miR-15b-5p is an independent predictive biomarker of LRC in HNSCC patients (HR=0.25; 95% CI=0.05-0.78; p<0.016). miR-15b-5p represents a potentially helpful biomarker for individualized treatment decisions concerning the management of HNSCC patients.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Head and neck cancers are a heterogenous group of epithelial tumors represented mainly by squamous cell carcinomas (HNSCC), which are the sixth most common type of cancer worldwide. Surgery together with radiotherapy (RT) is among the basic treatment modalities for most HNSCC patients. Various biomarkers aiming to predict patients' response to RT are currently investigated. The reason behind this effort is, on one hand, to distinguish radioresistant patients that show weak benefit from RT and, on the other hand, reduce the ionizing radiation dose in less aggressive radiosensitive HNSCC with possibly less acute or late toxicity.
MATERIALS AND METHODS
METHODS
A total of 94 HNSCC patients treated by definitive intensity-modulated radiotherapy were included in our retrospective study. We used a global expression analysis of microRNAs (miRNAs) in 43 tumor samples and validated a series of selected miRNAs in an independent set of 51 tumors.
RESULTS
RESULTS
We identified miR-15b-5p to be differentially expressed between patients with short and long time of locoregional control (LRC). Kaplan-Meier analysis confirmed that HNSCC patients with higher expression of miR-15b-5p reach a significantly longer locoregional relapse-free survival compared to patients expressing low levels. Finally, multivariable Cox regression analysis revealed that miR-15b-5p is an independent predictive biomarker of LRC in HNSCC patients (HR=0.25; 95% CI=0.05-0.78; p<0.016).
CONCLUSION
CONCLUSIONS
miR-15b-5p represents a potentially helpful biomarker for individualized treatment decisions concerning the management of HNSCC patients.
Identifiants
pubmed: 30850365
pii: 16/2/139
doi: 10.21873/cgp.20119
pmc: PMC6489689
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN15 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
139-146Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
PLoS One. 2009 Jul 27;4(7):e6377
pubmed: 19633716
Oncol Rep. 2010 Jan;23(1):113-9
pubmed: 19956871
Clin Chem. 2010 Jun;56(6):998-1006
pubmed: 20378769
Oncogene. 2012 Jan 26;31(4):432-45
pubmed: 21725369
Mol Cell. 2011 Sep 16;43(6):993-1004
pubmed: 21925387
Cancer Prev Res (Phila). 2012 Apr;5(4):665-74
pubmed: 22318752
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14470-5
pubmed: 22908280
Int J Dent. 2013;2013:650218
pubmed: 24260035
Molecules. 2014 May 05;19(5):5704-16
pubmed: 24802984
Eur J Cancer. 2014 Oct;50(15):2619-35
pubmed: 25103455
Radiat Res. 2015 Feb;183(2):196-207
pubmed: 25594541
PLoS One. 2015 Mar 25;10(3):e0121706
pubmed: 25807141
Oncotarget. 2015 Jun 30;6(18):16227-38
pubmed: 26023735
J Cell Physiol. 2016 Jan;231(1):25-30
pubmed: 26031493
Gigascience. 2015 Nov 25;4:54
pubmed: 26613016
Oncotarget. 2016 Mar 22;7(12):13634-50
pubmed: 26872369
J Oral Pathol Med. 2017 Mar;46(3):208-213
pubmed: 27442811
Oncotarget. 2016 Nov 8;7(45):74362-74379
pubmed: 27556186
Dis Markers. 2017;2017:8245345
pubmed: 28325958
Oncol Rep. 2017 May;37(5):2720-2726
pubmed: 28350138
Otolaryngol Head Neck Surg. 2017 Aug;157(2):239-251
pubmed: 28397583
Oncol Res Treat. 2017;40(6):318-319
pubmed: 28521323
Cancer. 2017 Dec 15;123(24):4841-4850
pubmed: 28841234
Cancer Manag Res. 2017 Aug 18;9:363-371
pubmed: 28860859
Oncotarget. 2017 Jul 13;8(33):55511-55524
pubmed: 28903437
Cancer Med. 2018 Mar;7(3):726-735
pubmed: 29473326
Nat Rev Clin Oncol. 2018 Sep;15(9):541-563
pubmed: 29784926
J Oral Pathol Med. 2018 Oct;47(9):864-872
pubmed: 30079604
Stem Cell Reports. 2018 Dec 11;11(6):1506-1522
pubmed: 30449704